Martha Donoghue
- Oncology top 5%
- Pulmonary and Respiratory Medicine top 5%
- Cancer Research top 10%
- Molecular Biology
- Pathology and Forensic Medicine top 10%
- Co-authors
- Richard PazdurLola A. Fashoyin‐AjeLisa RodríguezSteven J. LemeryMarc R. TheoretPatricia KeeganLeigh MarcusKirsten B. Goldberg
- Topics
- Childhood Cancer Survivors' Quality of Life (5 papers)Cancer Genomics and Diagnostics (5 papers)Pharmaceutical studies and practices (5 papers)
- Cited by
- OncologyCancer ResearchHepatology
- Partner nations
- United StatesNetherlandsSwitzerland
In The Last Decade
Martha Donoghue
25 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 89
- Oncology 696
- Pulmonary and Respiratory Medicine 400
- Cancer Research 285
- Molecular Biology 247
- Pathology and Forensic Medicine 163
Countries citing papers authored by Martha Donoghue
This map shows the geographic impact of Martha Donoghue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martha Donoghue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martha Donoghue more than expected).
Fields of papers citing papers by Martha Donoghue
This network shows the impact of papers produced by Martha Donoghue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martha Donoghue. The network helps show where Martha Donoghue may publish in the future.
Co-authorship network of co-authors of Martha Donoghue
This figure shows the co-authorship network connecting the top 25 collaborators of Martha Donoghue. A scholar is included among the top collaborators of Martha Donoghue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martha Donoghue. Martha Donoghue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 5 | |
| 2 | 4 | |
| 3 | 0 | |
| 4 | 16 | |
| 5 | 3 | |
| 6 | 33 | |
| 7 | 37 | |
| 8 | 3 | |
| 9 | 77 | |
| 10 | FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumorsbreakdown → | 330 |
| 11 | 9 | |
| 12 | 8 | |
| 13 | 61 | |
| 14 | 92 | |
| 15 | 20 | |
| 16 | 171 | |
| 17 | 50 | |
| 18 | 49 | |
| 19 | 39 | |
| 20 | 17 |
About Martha Donoghue
Martha Donoghue is a scholar working on Cancer Research, Oncology and Hepatology, having authored 27 papers that have together received 1.2k indexed citations. Recurring topics across this work include Childhood Cancer Survivors' Quality of Life (5 papers), Cancer Genomics and Diagnostics (5 papers) and Pharmaceutical studies and practices (5 papers). The work is most often cited by research in Oncology (696 citations), Cancer Research (285 citations) and Hepatology (128 citations). Martha Donoghue has collaborated with scholars based in United States, Netherlands and Switzerland. Frequent co-authors include Richard Pazdur, Lola A. Fashoyin‐Aje, Lisa Rodríguez, Steven J. Lemery, Marc R. Theoret, Patricia Keegan, Leigh Marcus, Kirsten B. Goldberg, Mengdie Yuan and Julia A. Beaver. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.